Search results for sgl
FiltersOpen Government Canada
4 datasets for “sgl”
- Open Government Canada
Summary Safety Review - Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors INVOKANA (canagliflozin) and FORXIGA (dapagliflozin) - Evaluation of a Potential Risk of Acute Kidney Injury
Health Canada | Santé CanadaUpdated 10 May 2024
… acute kidney injury and the use of two SGLT2 inhibitors, Invokana (canagliflozin) or Forxiga (dapagliflozin). This issue was …
- HTML
- Open Government Canada
Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Potential Risk of Bone-Related Side Effects
Health Canada | Santé CanadaUpdated 10 May 2024
… risk of bone-related side effects of using SGLT2 inhibitors. The review was triggered by a notice about …
- HTML
- Open Government Canada
Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Risk of the Body Producing High Levels of Acids in the Blood (diabetic ketoacidosis)
Health Canada | Santé CanadaUpdated 10 May 2024
Ketones are a type of waste product that the body creates when it breaks down fat to use …
- HTML
- Open Government Canada
Summary Safety Review - SGLT2 inhibitors - Assessing the potential risk of a rare brain condition (posterior reversible encephalopathy syndrome) in patients who have developed high levels of acids in the blood (diabetic ketoacidosis)
Health Canada | Santé CanadaUpdated 10 May 2024
… PRES in patients treated with SGLT2 inhibitors who have developed DKA. SGLT2 inhibitors have been linked to an …
- HTML